NCT03568981 is a clinical trial of Partial breast irradiation in Breast Cancer, sponsored by Yonsei University.

Who is sponsoring NCT03568981?

NCT03568981 is sponsored by Yonsei University.

What drugs are being tested in NCT03568981?

Interventions in NCT03568981: Partial breast irradiation, Whole breast irradiation.

What condition does NCT03568981 study?

NCT03568981 studies Breast Cancer.

Is NCT03568981 still recruiting?

NCT03568981 is currently status unknown. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT03568981

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer

Status unknown Last updated 26 June 2018

What this trial tests

trial testing Partial breast irradiation in Breast Cancer in 200 participants. Status unknown.

Timeline

11 April 2018

Primary endpoint
11 April 2023

11 April 2023

Quick facts

Lead sponsor	Yonsei University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	11 April 2018
Primary completion	11 April 2023
Estimated completion	11 April 2023
Sites	1 location across South Korea

Drugs / interventions tested

Partial breast irradiation
Whole breast irradiation

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Yonsei University

Who can join

20 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to investigate the effect of 5-fraction stereotactic partial breast irradiation and whole breast irradiation on patient-reported outcomes, cosmetic outcome, and breast tissue fibrosis in early-stage breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

First Experience in Korea of Stereotactic Partial Breast Irradiation for Low-Risk Early-Stage Breast Cancer.
Lee WH, Chang JS, Kim MJ, Park VY, et al · · 2020 · cited 8× · PMID 32411612 · DOI 10.3389/fonc.2020.00672
Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions.
Takanen S, Pinnarò P, Farina I, Sperati F, et al · · 2022 · cited 5× · PMID 36313648 · DOI 10.3389/fonc.2022.953810

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03568981 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03568981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing